What is MaxisIT?
MaxisIT is a recognized pioneer in eClinical Integration and Adaptive Decision Support software. Its flagship CT Renaissance® clinical enterprise suite is designed to integrate and orchestrate end-to-end functionalities within a uniform or hybrid plug-and-play architecture. This solution supports the pharmaceutical and life sciences industries by enabling the efficient, safe, and FDA-approved delivery of drugs, aiming to reduce costs and accelerate time-to-market. The company emphasizes strategic, enterprise-wide reusable and scalable solutions, complemented by world-class services and a long-term partnering strategy.
How much funding has MaxisIT raised?
MaxisIT has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.5M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.5M led by PPP
What's next for MaxisIT?
The substantial enterprise-level funding and recent strategic investment signal a strong growth phase for MaxisIT. This capital infusion is expected to fuel further development of its CT Renaissance® platform, enhance its market reach within the pharmaceutical and life sciences sectors, and potentially support strategic acquisitions or partnerships. The company's focus on interoperability, reusability, and scalability positions it to capitalize on the increasing demand for integrated clinical trial management systems and data analytics, driving innovation in drug discovery and approval processes.
See full MaxisIT company page
